Prolensa®
Bromfenac is an ophthalmic NSAID for postoperative ocular inflammation and pain following cataract surgery.
| Dosage Form | Ophthalmic Solution |
| Strength | 0.07%, 0.09% |
| Storage | Store at 15–25°C. |
| Category | Ophthalmics |
| Availability | Available for Transfer |
Postoperative inflammation and pain after cataract surgery.
Nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase (COX) enzymes (primarily COX-2), reducing prostaglandin synthesis and decreasing inflammation and pain.
Each Burrard Pharmaceuticals technology transfer package for Bromfenac includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.